AstraZeneca, Merck Say FDA Panel Recommends Lynparza in Pancreatic Cancer

Date : 12/17/2019 @ 8:05PM
Source : Dow Jones News
Stock : AstraZeneca PLC (AZN)
Quote : 49.31  0.2 (0.41%) @ 10:33PM
After Hours
Last Trade
Last $ 49.31 ◊ 0.00 (0.00%)

AstraZeneca, Merck Say FDA Panel Recommends Lynparza in Pancreatic Cancer

AstraZeneca (NYSE:AZN)
Historical Stock Chart

3 Months : From Nov 2019 to Feb 2020

Click Here for more AstraZeneca Charts.

By Michael Dabaie


AstraZeneca PLC (AZN) and Merck & Co. Inc. (MRK) said an U.S. Food and Drug Administration advisory panel voted to recommend lynparza for first-line maintenance therapy in pancreatic cancer.

The Oncologic Drugs Advisory Committee voted 7-5 to recommend lynparza as a first-line maintenance monotherapy for germline BRCA-mutated metastatic pancreatic cancer, the companies said.

The FDA in August accepted the supplemental New Drug Application for lynparza for this indication.

The ODAC provides the FDA with independent advice and recommendations on marketed and investigational medicines for use in the treatment of cancer. The FDA isn't bound by the committee's guidance but takes its advice into consideration.

In 2017, AstraZeneca and Merck unveiled an oncology collaboration to co-develop and co-commercialize lynparza.


Write to Michael Dabaie at


(END) Dow Jones Newswires

December 17, 2019 14:50 ET (19:50 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest AZN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.